HL156 compounds, novel metformin derivatives, inhibit angiogenesis through AMPK mediated downregulation FOXM1 in gastric cancer cells by 理쒗삙吏�
   
 
 
HL156 compounds, novel metformin 
derivatives, inhibit angiogenesis through AMPK 
mediated downregulation of FOXM1 
 in gastric cancer cells 
 
 
 
 
Hae-Ji Choi 
 
Department of Medical Science 
The Graduate School, Yonsei University
   
 
 
HL156 compounds, novel metformin 
derivatives, inhibit angiogenesis through AMPK 
mediated downregulation of FOXM1  
in gastric cancer cells 
 
Directed by Professor Jae-Ho Cheong 
 
The Master`s Thesis  
Submitted to the Department of Medical Science 
the Graduate School of Yonsei University 
in partial fulfillment of the requirements for the degree of 
 Master of Medical Science 
 
Hae-Ji Choi 
December 2014 
   
 
 
   
 
 
ACKOWLEDGEMENTS 
 
짧으면서도 길게 느껴졌던 2년 동안의 여정의 성과물인 학위 논문
을 완성 할 수 있게 되었습니다. 혼자 힘으로는 절대 이루어 낼 수 
없었을 것입니다. 2012년부터 처음 실험실 생활을 시작하면서 많은 
분들의 도움으로 지금까지 올 수 있었던 것 같습니다.  
먼저, 우리 지도 교수님, 정재호 교수님께 감사의 마음을 전합니다. 
아무것도 모르던 저에게 아낌없는 가르침과 관심 덕분에 제가 여기까
지 올 수 있었던 것 같습니다. 아직 부족하지만 교수님을 알게 되고 
교수님께 배울 수 있게 되어 정말 영광이고 감사합니다.  
학위 과정 동안 자문과 조언을 해주신 윤호근 교수님과 전경희 교수
님 두 분께 감사의 인사를 드립니다.  
처음 만났던 때가 지금도 생생하게 기억나는 우리 실험실 사람들 
박은성 교수님, 박기청 박사님, 기현정 박사님, 정민 언니, 이재은 
박사님, 심문희 선생님, 이도형 선생님, 박경호 선생님, 최윤영 선생
님 그리고 정말 많이 믿고 의지하고 같이 있어서 힘들어도 둘이어서 
웃으며 이겨낼 수 있었던 아라 모두 감사합니다. 
항상 잊지 않고 반갑게 맞이해주는 성락 오빠, 한슬 언니, 은정 언
니, 선영 언니 그리고 이곳에서의 소중한 인연들인 지혜, 지은, 인수 
오빠, 성호 오빠, 주만 오빠, 동국 오빠 모두에게 감사합니다.   
각자의 길을 열심히 가고 있는 오랜 친구들 수진, 혜영, 진희, 연
진, 가영, 금진, 세나 모두에게 고마움을 전합니다. 
마지막으로 저를 믿고 묵묵히 뒤에서 지켜봐 주시는 우리 가족 아빠, 
엄마, 오빠 감사하고 사랑합니다. 
 
최 혜 지 
   
 
 
TABLE OF CONTENTS 
 
 
ABSTRACT∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 1 
 
Ⅰ. INTRODUCTION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 3 
 
Ⅱ. MATERIALS AND METHODS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 9 
 
1. Reagents and Cell treatment∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 9 
2. Cell lines and culture conditions∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 9 
3. Western blotting∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 9 
4. MTS cell proliferation assay∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 10 
5. Matrigel morphogenesis assay∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 11 
6. Assessment of secreted VEGFA∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 11 
7. Nuclear protein extraction∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙11 
8. Electrophoretic mobility shift assay (EMSA) and super-shift assay∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 12 
9. Statistical analysis∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙12 
 
   
 
 
Ⅲ. RESULTS 
 
1. Effect of HL156 compounds on cancer cell proliferation∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 14 
2. HL156 compounds down-regulate endothelial cell network formation∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 16 
3. Regulation of VEGFA secretion by HL156 in gastric cancer cells∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 19 
4. HL156 represses expression of FOXM1, but not FOXO3A∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 21 
5. HL156 suppresses FOXM1 binding to the VEGFA promoter in vitro ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 24 
6. Increased AMPK activity by HL156 suppresses FOXM1 expression∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 26 
7. Effect of HL156 on cell cycle regulatory proteins that regulate phosphorylation of 
FOXM1∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 29 
  
Ⅳ. DISCUSSION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 33 
 
Ⅴ. CONCLUSION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 36 
 
REFERENCES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 46 
 
ABSTRACT (IN KOREA) ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 54 
  
   
 
 
LIST OF FIGURES 
 
Figure 1.  HL156 compounds structure formula∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙13 
Figure 2.   30μM HL156 compounds do not significantly inhibit 
proliferation of gastric cancer cells∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 15 
Figure 3.   HL156 compounds inhibit endothelial cell morphogenesis ∙∙∙∙18 
Figure 4.   HL156 compounds inhibit VEGFA secretion in gastric cancer 
cells ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 20 
Figure 5.   Expression of FOXM1 is repressed by HL156 compounds∙∙∙∙∙23 
Figure 6.   HL156 compounds suppress FOXM1 binding to the VEGFA 
promoter ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 25 
Figure 7.   Activation of AMPK by HL156 compounds suppresses 
expression of FOXM1∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 28 
Figure 8.   Downregulation of CDK4 corresponds to activation of AMPK∙∙∙∙ 
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙31 
Figure 9.  Proposed model for the mechanism of HL156 compounds 
mediated anti-angiogenesis∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 32 
 
   
1 
 
 
ABSTRACT 
 
 
HL156 compounds, a novel metformin derivative, inhibit angiogenesis through AMPK 
mediated downregulation of FOXM1 in gastric cancer cells 
 
 
Hae-Ji Choi 
 
Department of Medical Science 
The graduate School, Yonsei University 
 
 
(Directed by Professor Jae-Ho Cheong) 
 
Metformin, which is widely used as an anti-diabetic drug, has recently gained significant attention 
as a potential anti-cancer agent. Although a couple of potential mechanisms explaining anti-tumor 
effects have been suggested, its detailed molecular mechanisms remain elusive. HL156 compounds are 
novel biguanide derivatives based on metformin formula with more potent anti-tumor effects than 
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metformin. In cell based assays, HL156 activates AMP-activated kinase (AMPK) more potently than 
metformin in various cancer cell lines. 
Our preliminary analysis of Reverse phase protein array (RPPA) data from gastric cancer patients 
indicated that proteins related to regulating angiogenesis were increased in tumors of patients with poor 
prognosis. In addition, a pilot in vivo efficacy study showed that HL156 significantly suppressed 
metastasis in breast cancer xenograft models.  
Motivated by these, we hypothesized that HL156 would inhibit angiogenesis that is one of the 
critical steps of metastatic process. Further, the anti-angiogenic mechanism of HL156 would be 
mediated through AMPK activation which downregulated oncogenic transcription factor FOXM1.  
 Culturing HUVEC cells in the conditioned media treated with HL156 compounds to gastric cancer 
cells downregulated in vitro endothelial cell network formation. In the same conditioned media, the 
expression of VEGFA, a major angiogenic factor, was prominently suppressed. Also, the expression of 
FOXM1, a pleiotropic oncogenic transcription factor, was inhibited by HL156, which is correlated with 
activation of AMPK. To further interrogate the molecular mechanisms by which FOXM1 was down-
regulated, we assessed CDK4/6 expression in gastric cancer cells after HL 156 treatment. CDK4/6, 
which phosphorylates and activates FOXM1, was downregulated leading to the decrease of phospho-
FOXM1 (Ser35) level. Electrophoretic mobility shift assay showed that HL156 treatment repressed the 
FOXM1 binding to the VEGFA promoter.     
Taken together, these results suggest that HL156 alleviates tumor angiogenesis by VEGFA 
inhibition through AMPK mediated CDK4/6 - FOXM1 downregulation in gastric cancer cells. 
 
 
 
 
 
--------------------------------------------------------------------------------------------------------------------------- 
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Ⅰ. INTRODUCTION 
The biguanide metformin (1,1-dimethylbiguanide hydrochloride) is a widely used oral 
hypoglycemic agent for treatment of type 2 diabetes1. During the decades, epidemiologic, preclinical 
and clinical studies suggested the associations of diabetes and metformin with cancer. Metformin has 
recently gained significant attention as a potential anti-cancer agent that inhibits the proliferation of 
several human cancer cell lines including prostate 2, breast 3, colon 4, glial 5, and gastric cancer 6. 
AMP-activated protein kinase (AMPK) is a sensor of energy status that maintains cellular energy 
homeostasis by fine-tuning a range of diverse cellular processes. In mammals, there are seven genes 
   
4 
 
encoding AMPK, two isoforms of α (α1 and α2), two of β, (β1 and β2), and three of γ (γ1, γ2 and γ3). 
The α subunits contain a typical serine/threonine kinase domain at the N terminus; as for many protein 
kinase, these only having significant activity when phosphorylated by upstream kinases at conserved 
threonine residue within the activation loop (Thr172 in human α1)7 .  
Anti-cancer effect of metformin is known to be mainly mediated through the activation of 
LKB1/AMPK pathway 8. AMPK activation results in down-regulation of mammalian TOR complex1 
and the IGF-1/AKT pathways, and in p53-mediated cell-cycle arrest 9. Active AMPK leads to loss of 
cyclin D1 mRNA and protein and the decline in cyclin D1 levels causes the release of sequestered CDK 
inhibitors, p27Kip1 and p21Cip1, which then bind to and inhibit the cyclin E/CDK2 complex 10. 
Of note, metformin suppresses mitochondrial electron transport chain complex Ⅰ11, which is now 
recognized as a major effect of metformin mediated tumor suppression. When combined with 2-
deoxyglucose (2DG), metformin induces cancer cell death in vitro, significantly suppressed tumor 
growth in two distinct xenograft tumor models in vivo 12. Further, metformin decreases angiogenesis by 
increasing the anti-angiogenic thrombospondin-1 (TSP-1) in insulin resistant obese women13. Recently 
metformin demonstrated the anti-angiogenic effect through the suppression of VEGF expression, 
mediated by downregulation of the mTORC1/HIF-1α pathway 14. 
HL156 compounds, novel metformin derivatives with enhanced AMPK activating property, have 
proved tumor growth inhibition and anti-metastasis effect in breast cancer cell in vivo models at low 
concentrations. (Pilot study 1,2) 
Tumor metastasis is a multistage process during which malignant cells spread from the primary site 
to distant organs. The process of cancer metastasis consists of sequential and interrelated steps. Each of 
these can be rate limiting, because a failure or an insufficiency at any steps can halt the process 15, 16.  
Angiogenesis is a new blood vessel formation from pre-existing ones in the essential process of 
metastatic cascade. Extensive vascularization must be required for a tumor mass exceeding diameter of 
1-2mm 17. The synthesis and secretion of angiogenic factors has a critical role in establishing a capillary 
network within the surrounding host tissues 18. Local invasion of the host stroma by tumor cells occurs 
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by multiple mechanisms 16. Thin-walled venules and lymphatic channels, both of which offer very little 
resistance to penetration by tumor cells 19. After tumor cells have survived in the circulation, they 
become arrested in capillary beds of distant organs by adhering to vessel walls 20. Extravasation occurs 
next, by mechanisms similar to those that involved during the initial vascular invasion. Proliferation of 
the tumor cells within the organ parenchyma completes the metastatic process. The micrometastasis 
must establish vascularization 21 and defenses against host immune system to colonize and enter these 
processes for additional metastases 19, 20. 
Expression of the metastatic signature has been correlated with a poor prognosis and has been 
shown to be consistent in several types of cancer. A growing tumor needs an extensive network of 
capillaries for provision of nutrients and oxygen as well as for disposal of metabolic wastes 22. Therefore, 
tumor growth and metastasis are angiogenesis-dependent. 
 To initiate the formation of new capillaries, endothelial cells (ECs) of pre-existing blood vessels 
must degrade the underlying basement membrane and invade into the stroma of the neighbouring tissue 
by the activity of the plasminogen activator (PA) system and the MMPs (matrix metalloproteinases) 23. 
After proteolytic degradation of the ECM (extracellular matrix), endothelial cells migrate to the 
degraded matrix by a variety of growth factors including VEGF family 24, FGF-2 25 and angiopoietins 
26. The final phases of the angiogenic process, including the construction of capillary loops and the 
determination of the polarity of the endothelial cells, are mediated by cell adhesion molecules 27. 
VEGF/VEGF-receptor (VEGFR) axis plays a central role in angiogenesis. VEGF has been 
associated with tumor progression and poor prognosis in colorectal carcinoma 28, 29, gastric carcinoma 
30, 31, pancreatic carcinoma 32, 33, breast cancer 34, 35, prostate cancer 36, lung cancer 37 and melanoma 38.  
The mammalian VEGF family consists of five glycoproteins including VEGFA, VEGFB, VEGFC, 
VEGFD and placenta growth factor (PIGF) 24, 39. The most important molecule that controls blood-
vessel morphogenesis is VEGFA. VEGFA is required for the chemotaxis and differentiation of 
endothelial precursor cells (EPCs), EC proliferation, the direct assembly of ECs into vasculogenesis 
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and angiogenic remodelling 40. Under hypoxic conditions, VEGF transcription is upregulated by 
hypoxia-inducible factors (HIF) 41, 42.  
  Targeting the VEGF pro-angiogenic signalling pathway with various inhibitors has led to FDA 
approval of angiogenesis inhibitors as cancer therapeutics 43. A ligand-trapping monoclonal antibody 
bevacizumab (Avastin, Genetech/Roche), and two kinase inhibitors (sorafenib (Nexavar, Bayer) and 
sunitinib (Sutent, Pfizer)) targeting the VEGF receptor (VEGFR) tyrosine kinases are clinically tested 
for the proof-of-concept for anti-angiogenesis therapy 44. However, inherent or acquired resistance to 
VEGF pathway inhibitors can occur in most patients, leading in some cases to a lack of response and 
in others to disease recurrence 45. 
VEGF effects on cell survival have been shown to be mediated by Flk1/VEGFR2-PI3K-Akt 
pathway 46, 47. Akt is a critical regulator of PI3K-mediated cell survival 48, 49. In many tumors, AKT is 
overexpressed or amplified with elevated level of AKT phosphorylation 50, 51.  
 PI3K/AKT signaling pathway also plays an important role in regulating the vasculature and 
angiogenesis52, 53. PI3K/AKT regulates tumor angiogenesis by down-stream targets such as 
mTOR/p70S6K1 signaling axis, the inhibition of FOXO, the induction of NO 54, 55, and the inhibition 
of GSK-3β.  
The forkhead box O (FoxO) transcription factors FOXO1 and FOXO3A are critical regulators of 
endothelial sprout formation and migration in vitro 56. Inhibition of Foxo1 activity in mature endothelial 
cells, has been reported to be an important mechanism through which angiopoietin 1 (Ang1) modulates 
endothelial function 57, and inhibition of FOXO factors promotes endothelial proliferation 58. In addition, 
FOXO3A represses the proximal VEGF promoter through FOXM1 dependent and independent 
mechanisms in breast cancer 59. Forkhead box protein M1 (FOXM1) belongs to the forkhead 
superfamily of transcription factors which are identified by an evolutionary conserved 
Forkhead/winged-helix DNA-binding domain 60, 61. It is previously known as Trident (in mouse) 62, 
HFH-11(in human) 63, WIN or INS-1(in rat) 64, MPP-2 (partial human cDNA) 65 or FKHL-16 66. The 
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human FOXM1gene is a 10-exon structure spanning approximately 25 kb on the 12p13-3 chromosomal 
band 62.  
The FOXM1 transcription factors are crucial for G1-S and G2-M cell cycle phase progression and 
mitotic spindle integrity 67. FOXM1 regulates a variety of biological processes in mammalian cells 
through regulating the transcription of genes important for cell cycle progression, cell proliferation, 
survival, cell differentiation, DNA damage repair, angiogenesis, cell migration, and chemotherapeutic 
drug response 68. FOXM1 expression is stimulated by oncogenes and growth factors and inhibited by 
p53. Rb and p19Arf inhibit activity of FOXM1. A new study showed that FOXM1 could stimulate 
expression of genes involved in various steps of tumor metastasis 69, including epithelial-mesenchymal 
transition (EMT), cell migration, and premetastatic niche formation. 
The FOXM1 protein exists in three different isoforms. Both FOXM1B and C splice variants are 
transcriptionally active, whereas FOXM1A is transcriptionally inactive, due to the disruption of the 
transactivation domain in FOXM1A 63. FOXM1 is a proliferation specific mammalian forkhead 
transcription factor: its expression is restricted to cells that are proliferating 61. The FOXM1 gene 
exhibits a specific expression pattern during the cell cycle. Both FOXM1 mRNA and protein levels 
increase at the entry to the S-phase of the cell cycle and remain elevated during the G2 and M-phases 
62. The transcriptional activity of FOXM1 is also cell cycle-restricted, and depends on its 
phosphorylation level, reaching maximum levels in the G2/M transition. Based on the putative 
consensus phosphorylation sites, kinases such as CDK2, CDK1, mitogen-activated protein kinase 
(MAPK) and Plk-1 may be involved in FOXM1 phosphorylation. FOXM1C is strongly activated by 
cyclin D1/CDK4 and antagonistically regulated by cyclin D1/CDK4 and RB 70. CDK4/6 initiate 
FOXM1 phosphorylation, by that means resulting accumulation of FOXM1 in cells, thereby activate 
and stabilize FOXM1 by direct multisite phosphorylation 71. Cyclin-CDK-dependent phosphorylation 
of the C-terminal region of FOXM1 increases transcriptional activation causing recruit a transcriptional 
co-activator, the histone deacetylase p300/CREB binding protein (p300/CBP). FOXM1 also interacts 
with CDK inhibitor p27kip which inhibits Cyclin-CDK kinase 61. MAPK-mediated phosphorylation of 
FOXM1 was shown to regulate subcellular localization and transcriptional activation72. FOXM1 
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possesses 5 RXL (cyclin binding) motifs and 15 CKD consensus sites, 12 of which are localized in its 
C-terminal transactivation domain (TAD)71.  
Cyclin-dependent kinases (CDKs) govern cell cycle phase transitions in mammals and boost global 
gene transcription. Cyclin D-dependent kinases (CDK4 and CDK6) have been identified as the major 
oncogenic drivers among cell cycle CDKs. At the mechanistic level, recent studies have revealed pro-
tumorigenic functions of CDK4/6 beyond cell cycle progression. Cells possess three distinct families 
of regulatory subunits: activating D-type cyclins, negative regulatory INK4 proteins and Cips/Kips, 
which can act as both inhibitors and activators, depending of their phosphorylation status 73. 
Gastric cancer is the second most leading cause of cancer-related death worldwide 21, and the 
overall prognosis of advanced gastric cancer is poor 74. In gastric cancer, expression of AKT and 
phosphorylated AKT (p-AKT) are detected in 74% and 78% of tumors respectively 75. In a report of 50 
advanced gastric carcinomas, there was a statistically significant correlation between p-AKT expression 
and depth of tumor, number of involved lymph nodes and poor prognosis 76. Compared with other more 
extensively investigated cancers, such as breast, prostate, and colon carcinoma, the molecular 
mechanisms involved in the transformation and progression of gastric cancer are poorly characterized 
77. 
Our preliminary analysis of Reverse phase protein array (RPPA) data from gastric cancer patients 
indicated that p-AKT, PAI1, VEGFR2 and p-FOXO3A all of which related with angiogenesis were 
increased in tumors of patients with poor prognosis. Together with a pilot study that demonstrated anti-
metastasis effect of HL156 in in vivo breast tumor mouse models, we were prompted to test the 
hypothesis that HL156 inhibits angiogenesis. In this study, we demonstrated that HL156 compounds 
suppress VEGFA expression in gastric cancer cell line models. Further, we found that the 
downregulation of oncogenic transcription factor FOXM1, which transcriptionally activates VEGFA 
expression, is mediated through inhibition of cyclin D-dependent kinase, CDK4/6 by AMPK activation.  
 
 
   
9 
 
Ⅱ. MATERIALS AND METHODS 
 
1. Reagents and Cell treatment 
Cells were cultured in 10-cm dishes containing 10ml of the medium. After attachment for 
24hours and growth 80% confluence, the cells were treated with 30μM HL156 compounds. A 
stock solution of 25mM HL156 compound was dissolved and diluted with distilled water to 
obtain final concentrations of 30μM. Compound C (Merck KGaA, Darmstadt, Germany), the 
AMPK inhibitor, was stocked at a concentration of 20mM (dissolved in DMSO) and was 
diluted with DMSO for the final doses of 20μM (0.1% DMSO). Control cells were treated with 
an equal amount of distilled water or DMSO.  
 
2. Cell lines and culture conditions 
       MKN28 and AGS cells were maintained in RPMI-1640 medium containing 10% (v/v) fetal 
bovine serum (FBS), 100 units/ml penicillin, and 100 ug/ml streptomycin. Human umbilical 
cord endothelial cells (HUVECs) were maintained in EGM-2 Bulletkit (contains FBS, 
Hydrocortisone, hFGF-B, GA-1000, hEGF, Heparin, VEGF, R3-IGF-1, ascorbic acid) 
purchased from Lonza (Walkersville, MD USA). Cells were grown at 37℃, 5% CO2 
humidified incubator. 
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3. Western blotting 
Protein lysates were prepared from cells at 90% confluency. The cells were then washed in ice-
cold phosphate buffered saline (PBS) and then extracted in a lysis buffer containing 1% Triton 
X-100, 50mmol/L HEPES (pH7.5), 150mmol/L NaCl, 25mmol/L β-glycerophosphate, 25 
mmol/L NaF, 5mmol/L EGTA, 1mmol/L EDTA as a protease inhibitor cocktail (Roche 
Diagnostics, Indianapolis, IN). The lysates were centrifuged at 13,000 rpm for 30min and 
frozen at -80℃ until use. Protein concentrations were determined using a bicinchoninic acid 
protein assay kit (Pierce, Rockford, IL, USA). Samples were electrophoresed using 8% SDS-
PAGE, and proteins were transferred to PVDF membranes. The membranes were incubated 
with primary antibodies after blocking and then were incubated with HRP-conjugated 
secondary antibodies. Immunoreactive proteins were visualized with an enhanced 
chemiluminescence detection system on X-ray film. In this study, the following antibodies 
were used : anti-β-actin monoclonal antibody (Sigma-Aldrich;A5441, used at 1:1000), 
FOXM1 (Cell signaling, #5436, used at 1:1000), FOXO3A (Cell signaling, #2497, used at 
1:1000), FOXO1 (Cell signaling, #2880, used at 1:1000), Phospho-FOXM1(Ser35) (Cell 
signaling, #14170, used at 1:1000), cyclin D1( Cell signaling, #2926, uses at 1:1000), CDK4 
(Cell signaling, #12790, used at 1:1000), CDK6 (Cell signaling, #3136, used at 1:1000), p27 
(Santa cruz, sc-528, used at 1:1000), Phospho-AMPKα (Thr172) (Cell signaling, #2535, used 
at 1:1000), AMPKα (Cell signaling, #2532, used at 1:1000), HIF1α (millipore, #07-628, used 
at 1:1000). 
 
4. MTS cell proliferation assay 
Cell proliferation assays were conducted using the MTS assay (Promega Corporation, Madison, 
WI, USA) according to the manufacturer`s instructions. Each cell line (1X104) was seeded into 
a well of a 96-well plate and cultured in 100㎕ of RPMI-1640 supplemented with 10% FBS. 
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After 24hours, seeding cells were treated with 10nM, 100nM, 1μM, 100μM, 500μM, 1mM 
HL156 compound or, as a control, without HL156 compound. After treatment, 20㎕ MTS[(3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)], 
was added to each well and the cells were incubated at 37℃ with 5% CO2 for 4 hours. 
Absorbance was measured for each well at a wavelength of 490nm using an ELISA reader.  
 
5. Matrigel morphogenesis assay 
150㎕ of growth factor reduced BD Matrigel matrix basement membrane (BD Biosciences, 
San Jose, CA, USA) was pipetted into each well of a 24-well plate and polymerized for 30 min 
at 37℃. Human umbilical vein endothelial cells (HUVECs) were harvested after trypsin 
treatment and suspended in conditioned medium. Next, 2X104 HUVECs in 500㎕ of 
conditioned medium were added to each well and incubated at 37℃ in 5% CO2 for 4hours. 
We then photographed the cultures under a bright-field microscope. The quantified results were 
expressed in number of master segments and meshes. 
 
6. Assessment of secreted VEGFA 
MKN28 and AGS cells were treated with 30μM HL156 compounds for 48hours. Supernatant 
medium was collected and VEGFA concentrations were measured using commercially 
available sandwich ELISA kits (Thermo scientific, Waltham, MA, USA). 
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7. Nuclear protein extraction 
Nuclear and cytoplasmic extracts were prepared using NE-PER nuclear and cytoplasmic 
extraction reagents (Thermo scientific, Waltham, MA, USA). For adherent cells, harvest with 
trypsin-EDTA and then centrifuge at 500 X g for 5 minutes. Wash cells by suspending the cell 
pellet with PBS. Transfer 1-10X106 cells to a 1.5ml microcentrifuge tube and pellet by 
centrifugation at 500Xg for 2-3 minutes.  Use a pipette to carefully remove and discard the 
supernatant, leaving the cell pellet as dry as possible. Add ice-cold CERⅠ to the cell pellet. 
Proceed to Cytoplasmic and Nuclear Protein Extraction, using the regent volumes indicated.  
 
8. Electrophoretic mobility shift assay (EMSA) and super-shift assay 
The DNA-protein binding detection kit (Promega, Madison, WI, USA) was used with 
modifications. In brief, DNA-protein binding reactions were carried out in a final volume of 
25 μl of buffer containing 10 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% 
(w/v) glycerol, 0.1 mg/ml sonicated salmon sperm DNA, 15 μg of nuclear extract, and 
oligonucleotides. Oligonucleotides containing FOXM1 binding consensus sequence were end-
labeled to a specific activity of 5ⅹ105 CPM with γ-[32P]-ATP and T4-polynucleotide kinase, 
followed by purification on a Nick column (GE Healthcare, Piscataway, NJ). Reaction mixtures 
with radio-labeled oligonucleotides were incubated at room temperature for 20 minutes, and 
resolved on 6.5% non-denaturing polyacrylamide gels after addition of 3 μl bromophenol blue 
(0.1%). Gels were dried and subjected to autoradiography. For super-shift assays, 3 μg of 
antibody was added for 20 minutes at room temperature after the initial incubation. Abs 
specific for FOXM1 were purchased from Cell Signaling Technology. 
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9. Statistical analysis 
Hierarchical cluster analysis was done using Cluster and Treeview. The reproducibility and 
correlation of results were tested by calculating Pearson Correlation Coefficients. The 
associations between protein feature and mutation status within cell line clusters were 
determined by x2 and Fisher`s exact testing. Analysis of statistical associations between drug 
sensitivity and RPPA clusters were done using one-way ANOVA. All statistical analyses were 
done in the R language environment. 
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Ⅲ. RESULTS 
HL156271 (HL156A) 
 
 
 
N-(N-(4-(trifluoromethoxy)phenyl)carbamimidoyl)pyrrolidine-1-carboximidamide acetate 
HL156277 (HL156B) 
 
 
 
 
N-(N-(4-(trifluoromethyl)phenyl)carbamimidoyl)pyrrolidine-1-carboximidamide acetate 
Figure 1. HL156 compound structure formula 
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1. Effect of HL156 compounds on cell proliferation  
Our pilot study showed that new potential metformin derivative HL156 (Fig. 1) inhibits tumor 
proliferation in vivo. Xenograft tumor model was established by injecting human colorectal carcinoma 
HCT116 cells in nude mice. HL156 showed comparable tumor growth inhibition effect at lower dose 
(50mpk) compared to capecitabine (Xeloda® ) (100mpk) (Pilot study). Based on this result, we wanted 
to evaluate the effect of the growth inhibition activity of HL156 on human gastric cancer cells. We 
examined the effect of HL156 on proliferation in two gastric cancer cell lines, MKN28 and AGS. Cells 
were grown in 10% FBS and treated 10nM, 100nM, 1μM, 100μM, 500μM, 1mM HL156 compound or, 
as a control, without HL156. The cell proliferation assay was conducted 3 days after the addition of the 
compound by MTS assay. HL156 slightly decreased cell proliferation in a dose-dependent manner in 
MKN28 and AGS cells. Based on this result, we determined 30μM for working concentration of HL156 
to interrogate the biological effects of HL 156 on tumor cells at the concentration that does not induce 
cellular toxicity (Fig. 2). 
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Figure 2. 30μM HL156 compounds do not significantly affect proliferation of gastric cancer cells. 
AGS and MKN28 were seeded in 96-well plates. After 24 hours, HL156 compounds were added to the 
culture medium and viability assay was conducted daily from 0 to 72 hours. MTS assay was conducted 
as described in Materials and Methods. The data points represent the mean cell number from 3 
independent experiments and error bars represent standard deviation. 
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2.  HL156 compounds down-regulate endothelial cell network formation 
Metformin has been reported to inhibit the proliferation of several cancer cell lines2-5 . However, 
there are few studies reporting effects on angiogenesis by metformin13, 78, 79.  
In our pilot study, HL156 showed anti-metastasis effect in MDA-MB-231 breast cancer mouse 
models. Based on these, we hypothesized that HL156 would inhibit angiogenesis which is one of the 
critical steps of metastatic process. 
We evaluated this idea using an endothelial cell tube formation assay. Endothelial cells cultured in 
the conditioned media from MKN28 or AGS cells treated with 30μM HL156 for 48hours had a 
significantly reduced capillary tube formation compared with the conditioned media from cells treated 
with vehicle alone as shown by the decreases in the number of segments and meshes (Fig. 3). Taken 
together, these results suggested that the decreased in vitro capillary tube formation by HL156 might be 
mediated by humoral factors secreted from cancer cells.  
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Figure 3. HL156 compounds inhibit endothelial cell morphogenesis. 
The angiogenic potential of gastric cancer cells treated with HL156 was determined by an endothelial 
cell matrigel tube formation assay. Samples of conditioned media were prepared from MKN28 and 
AGS cells. Human umbilical cord endothelial cells (7 X 104) in 500 ㎕ of conditioned media were 
then plated on growth factor-reduced Matrigel to form a capillary tube. Data from three independent 
tube formation experiments. Master segments and meshes were quantified by Angiogenesis Analyzer 
for ImageJ software. Bar graph shows the mean and standard deviation of the measured Master 
segments and meshes (n=3). Statistical significance (P < 0.05) in a comparison of HL156 treated and 
control groups. 
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3. Regulation of VEGFA secretion by HL156 compounds in gastric cancer cells 
Based on the above results, we next determined the expression of VEGFA, a secreted major 
angiogenic protein, in the conditioned media with or without HL156 treatment. Conditioned media from 
untreated MKN28 and AGS cells showed high levels of secreted VEGFA protein. On the other hand, 
treatment of HL156 on cancer cells decreased VEGFA levels in the conditioned media (Fig. 4A). In 
concordance with ELISA results, VEGFA protein levels were decreased by HL156 in AGS cells (Fig. 
4B). 
 
A. 
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B.                    AGS 
 
 
 
 
 
Figure 4. HL156 compounds inhibit VEGFA secretion in gastric cancer cells 
A. VEGFA concentrations in conditioned media of HL156 treated gastric cancer cells were measured 
by a quantitative sandwich enzyme immunoassay according to the manufacturer`s protocol (Human 
VEGFA ELISA kit, Thermo scientific). The optical density was measured at 450nm and 550nm using 
an ELISA plate reader. B. In parallel, VEGFA protein levels of these HL156 compounds treated AGS 
cells were also analyzed by western blotting. β-actin as a loading control. 
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4. HL156 represses expression of FOXM1, but not FOXO3A 
HIF-1α is one of the characteristics of solid tumors that promote the production of VEGF and 
angiogenesis80. Therefore, we investigated the expression levels of HIF-1α, but there are no significant 
changes in HIF-1α after HL156 treatment (supplementary Fig.3), indicating the effect of HL156 on 
VEGFA expression might be independent of HIF-1α.  
Our preliminary analysis of Reverse phase protein expression array (RPPA) data from gastric cancer 
patients indicated that p-AKT, PAI1, VEGFR2 and p-FOXO3A were increased in tumors of patients 
with poor prognosis. Since AKT, PAI1 and VEGFR2 are well-established angiogenesis related proteins, 
we speculated that FOXO3A would also regulate angiogenesis in gastric cancer. FOXO3A, one of 
FOXO transcription factors, is a critical regulator of endothelial sprout formation and migration in vitro. 
In addition, FOXO3A represses the proximal VEGFA promoter through FOXM1 - dependent and - 
independent mechanisms in breast cancer59. Overexpression of FOXM1 promotes cell-cycle 
progression, angiogenesis, invasion and metastasis81, 82. In contrast, loss of FOXO3A activity may 
increase resistance to apoptosis and cell cycle progression67.  
Thus, we speculated that the anti-angiogenic mechanism of HL156 would be regulated by FOX 
protein, especially FOXO3A and FOXM1 which have antagonistic role in angiogenesis. We first 
monitored the expression of FOXO3A and FOXM1 upon HL156 treatment of gastric cancer cells. 
Western blot analysis showed that HL156 treatment of MKN28 and AGS cells caused a decrease in 
FOXM1, but had little effects on FOXO3A (Figure. 5A). In other gastric cancer cell lines including 
MKN45, NCI-N87, SNU638 the same results have obtained (Supplementary Fig. 2). Having a similar 
endothelial sprout formation function like FOXO3A, FOXO1, the other forkhead family member, 56 
also showed few changes (Supplementary Fig. 3). In sharp contrast, nuclear FOXM1 was eminently 
downregulated by HL156 treatment, profoundly by HL156 B in particular, but no change in nuclear 
FOXO3A (Fig. 5B). These results suggest that FOXM1 is specifically down-modulated among forkhead 
proteins by HL156. 
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A. Total 
 
 
 
 
 
B. Nucleus 
 
 
 
 
 
 
 
Figure 5. Expression of FOXM1 is repressed by HL156 compounds  
A. Total protein was isolated at 24 and 48h following HL156 treatment. Western blot analysis showed 
that the level of FOXM1 was reduced in gastric cancer cells (MKN28 and AGS) when treated with 
HL156 A/B (30μM) for indicated time points.  B. Nuclear and cytoplasmic extracts were prepared at 
the times indicated, separated on polyacrylamide gels and subjected to immunoblotting with FOXM1 
and Lamin A/C used for nuclear marker. 
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5.  HL156 suppresses FOXM1 binding to the VEGFA promoter in vitro 
Recently VEGFA was reported to be a direct transcriptional target of FOXM183. To determine 
whether FOXM1 binding to VEGFA promoter is affected in response to HL156 treatment, we 
performed electrophoretic mobility shift assays using FOXM1 binding sequences 5`-TAATCA-3` 64 in 
VEGFA promoter.  
We found that FOXM1 binding region in VEGFA promoter specifically bound to nuclear extract  
prepared from MKN28 cells not treated with HL156 compound resulting in the formation of major 
shifted band while no detectable binding was noticed in the samples treated with HL156 (Fig. 6). 
Furthermore, the shifted band could be supershifted by the anti-FOXM1 antibody. Together with 
immunoblot results in Fig. 5B, these results indicate that HL156 compounds inhibit FOXM1 expression, 
particularly in the nucleus, thereby impeding binding to FOXM1 specific motif in the VEGFA promoter. 
Of note, the intensity of shifted bands between HL156A and HL156B treatment was different 
proportional to protein amounts in immunoblot assay (Fig. 5B), further confirming the nuclear FOXM1 
specifically binds to VEGFA promoter.  
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A.  
 
B. 
 
Figure 6. HL156 compounds suppress FOXM1 binding to the VEGFA 
A. Binding of FOXM1 to the VEGFA promoter in vitro. We performed EMSA using nuclear protein 
(NE) extracted from MKN28 cells and the oligonucleotide probes of putative FOXM1 binding region 
of VEGFA promoter. A major shifted band was noted and was competed out by an excess of unlabeled 
FOXM1 binding region oligonucleotide, and supershifted by anti-FOXM1 antibody. B. Sequences and 
positions of the VEGFA promoter. 
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6.  Increased AMPK activity by HL156 suppresses FOXM1 expression 
AMPK is a key energy sensor regulating normal and cancer cell metabolism and bioenergetics 
homeostasis. AMP which is elevated when cellular energetics are depressed activates AMPK by 
promoting its phosphorylation at Thr172 and by direct activation via an allosteric AMP site 84.  
It is well known that metformin activates AMPK. Metformin is thought to activate AMPK by 
inhibition of ComplexⅠof the respiratory chain, which leads to a decrease of intracellular ATP levels 
85. AMPK has a general role in coordinating growth and metabolism according to the cellular 
bioenergetics level 86. It is reported that when AMPK activity increased, the expression of FOXM1 
decreased in mouse hearts after birth 87. Further, activation of AMPK inhibits cervical cancer cell 
growth through reducing the expression of FOXM1 88. 
HL156 is a designed new compound with enhanced property of AMPK activation compared to 
metformin. It is, therefore, of interest to determine if AMPK activation in HL156 treated cells 
downregulates FOXM1.  
The results show that HL156 promotes AMPK Thr172 phosphorylation demonstrated by using anti-
phospho-AMPK antibody and that this correlates with downregulation of FOXM1 in both MKN28 and 
AGS cells (Fig. 7A).  
To further interrogate the role of AMPK in FOXM1 downmodulation, MKN28 cells were pretreated 
with compound C, a potent reversible AMPK-specific inhibitor, or DMSO (vehicle) for 30 min and 
then treated with or without HL156 (30μM) for an additional 48 hours. Pretreatment with compound C 
inhibited AMPK activation and rescues the reduction of FOXM1 levels caused by HL156 (Fig. 7B). 
These results indicate that downregualtion of FOXM1 by HL156 is mediated through AMPK activity.  
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B. 
 
 
 
 
 
 
Figure 7. Activation of AMPK by HL156 compounds suppresses expression of FOXM1  
A. Western blot analysis showed that the level of p-AMPKα (Thr172) was increased, while the level of 
FOXM1 was reduced in gastric cancer cells (MKN28, AGS) when treated with HL156 (30μM) for 
indicated times. B. Pre-treatment of AMPK inhibitor, compound C (20μM) reverses the effects of 
HL156 compound and recues the level of FOXM1. 
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7. Effect of HL156 on cell cycle regulatory proteins which regulated phosphorylation of FOXM1 
 
Next, we raised a question about molecular players that mediate AMPK activation and 
downregulation of FOXM1. The transcriptional activity of FOXM1, which follows its phosphorylation 
status, also increases and peaks at the G2/M transition 89. Activation of cyclin D dependent kinase is 
regulated by D-type cyclins, negative regulatory INK4 proteins and Cips/Kips which can act as both 
inhibitors and activators 73. Reliance of the abundance and stoichiometry of the three regulator subunits 
(D-cyclins, Cip/Kips, INK4) in the cell, each of the catalytic subunits (CDK4 or CDK6) can either bind 
to a D-type cyclin and a Cip/Kip protein, thus forming a trimeric holoenzyme 73. Down-regulation of 
FOXM1 using siRNA reduced expression of cyclin D1, increased expression of CDK inhibitor p27kip90. 
FOXM1 is identified that it is stabilized and activated by CDK4/6 as a multisite phosphorylation target71. 
Multisite phosphorylation of FOXM1 (Ser4, Ser35, Ser331, Ser451, Ser489, Ser508, Thr510, Ser522, 
Thr600, Thr611, Thr620, Thr627, Ser638, Ser672, Ser704) by cyclin D-CDK4/6 protected FOXM1 
from degradation. Metformin reduces cyclin D1 2, 10, cyclin D- dependent kinase (CDK) 4, CDK6 in 
human gastric cancer cell lines 6.  
We hypothesized that activation of AMPK by HL156 compound inhibits CDK4/6, decreases FOXM1 
phosphorylation, and reduces FOXM1 accumulation in the nucleus, thereby decreasing binding of 
FOXM1 to the VEGFA promoter.  
The protein levels of CDK4 significantly declined 48h after the treatment of HL156 compound. On 
the contrary, the CDK inhibitor p27kip expression elevated in cells treated with HL156 (Fig. 8). 
Phospho-FOXM1 (Ser35), one of the N-terminal CDK4/6 target sites, also significantly  decreased, 
concordant with the above result. Taken together, our data suggest that increased AMPK activity down-
regulates FOXM1 mediated by CDK4/6 suppression. 
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Figure 8. Downregulation of CDK4 corresponds to activation of AMPK 
Expression of CDK4 decreased in both MKN28 and AGS cells treated with HL156 for 48 hours. 
Consequently, phospho - FOXM1 (Ser35), a main phosphorylation site by CDK4/6, was also decreased. 
Western blotting of Cyclin D1, CDK4, CDK6, and phosphorylated FOXM1 (Ser35) in both MKN28 
and AGS cells of 24 and 48 hours after the addition of 30μM of HL156. 
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Figure 9. Proposed model for the mechanism of HL156 compounds mediated anti-angiogenesis 
Activation of AMPK leads to downregulation of CDK4/6 proteins. The reduction in CDK4 affects 
phosphorylation level of FOXM1. As unphosphorylated FOXM1 being increased, transcriptional 
activity of FOXM1 decreases due to protein degradation. Thus, AMPK→CDK4/6→FOXM1 signaling 
blocks transcription of FOXM1 target genes, especially VEGFA.  
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Ⅳ. DISCUSSION 
To summarize, the results presented here are consistent with a model in which increased 
phosphorylation and activation of AMPK by HL156 compounds leads to the downregulation of 
oncogenic transcription factor FOXM1, resulting in the anti-angiogenic effects.                        
We here discovered the anti-angiogenic effect of a novel potent metformin derivative, HL156 on 
VEGFA secretion in gastric cancer cells. We found that VEGFA secretions were significantly reduced 
by HL156. These suppressive effects were observed at 30uM, which did not significantly affect the 
proliferation of gastric cancer cells, a very lower concentration than that used in traditional anti-cancer 
studies on metformin (5-20 mM) 91. Moreover, we found that HL156 specifically suppressed oncogenic 
transcription factor FOXM1 which regulates VEGFA expression through direct binding to Forkhead 
binding elements (FHRE) of VEGFA promoter region 68.  
AMPK activation has been demonstrated a potent anti-proliferation effect in cancer 2 and we 
questioned whether this might be related with inhibition of angiogenesis. Downregulation of FOXM1 
in response to metformin has been demonstrated in cervical cancer cells through AKT/FOXO3A 
signaling pathway 88. Our data showed that the reduction of FOXM1 expression is correlated with 
activation of AMPK, however, the inhibition of FOXO3A by AKT is not reduced when AMPK is 
activated. Using compound C, a specific inhibitor of AMPK, reversed HL156 induced downregulation 
of FOXM1 in gastric cancer cells. HL156 B also more powerfully downregulates FOXM1 than HL156 
A. It remains to be determined appropriate Compound C concentration to use for HL156 B in further 
studies. Our results suggest that nuclear FOXM1 expression was inhibited by HL156 (Fig. 5B).  
FOXM1 has been reported to crosstalk not only with vascular endothelial growth factor (VEGF) 
signals, but also with multiple oncogenic pathways, such as phosphatidylinositol 3-kinase (PI3K)/Akt, 
nuclear factor-κB (NF-κB), sonic hedgehog (Shh), extracellular signal-regulated kinase (ERK), 
mitogen-activated protein kinase (MAPK), cyclooxygenase-2 (COX-2), epidermal growth factor 
receptor (EGFR), estrogen receptor (ER), c-myc, p53, reactive oxygen species (ROS), and hypoxia-
inducible factor-1 (HIF-1) signaling 92. 
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Surprisingly, the analysis from comprehensive molecular evaluation of primary gastric 
adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project revealed that significantly 
elevated FOXM1 and PLK1 signaling 93. Therefore, FOXM1 is an attractive and potential target for 
anticancer therapeutics 93. 
Transcription factors are traditionally thought to be “undruggable” because of transcription factor is 
a unapproachable nuclear event by therapeutic agents 94. We have a tool, small molecule inhibitor such 
as HL156 compound, to target FOXM1, a pleiotropic transcription factor that have multitude of 
oncogenic effects including angiogenesis, stemness, drug resistance, and EMT. 
FOXM1 regulates a variety of biological processes through regulating the transcription of genes 
important for cell cycle progression, cell proliferation and survival, cell differentiation, DNA damage 
repair, angiogenesis, cell migration and chemotherapeutic drug response 68. FOXM1 is required for β-
catenin nuclear accumulation in tumor cells, that nuclear FOXM1 and β-catenin form a functional 
complex with TCF4 on Wnt target-gene promoters, and that the functional interaction between FOXM1 
and β-catenin promotes cancer cells self-renewal and tumorigenesis 95.  Thus, it is tempted to target 
Wnt/β-catenin signaling pathway of which aberrant activation is widespread in human cancers for 
therapeutic intervention by HL156. We also found that HL156 inhibits migration of gastric cancer cells 
(Supplementary Fig.1). The role for FOXM1 in the regulation of MMP-2 and MMP-9 expression which 
related with tumor invasion, metastasis and angiogenesis, is demonstrated in various cancers 96.  
From meta-analysis of clinical trials of VEGF inhibitors other than bevacizumab, which include data 
on 4679 patients from 10 clinical trials, these drugs were associated with fatal adverse events at a rate 
that was about twice that seen in the placebo groups 97. There are similar data on bevacizumab, a 
monoclonal antibody that binds to VEGF. The data on bevacizumab came from a meta-analysis of 
clinical trials involving 10,217 patients, which found a significantly higher rate of fatal adverse events 
associated with bevacizumab than with chemotherapy alone. Based on our results, we anticipate that 
HL156, a new class angiogenesis inhibitor, has a competitive advantage over existing anti-angiogenic 
drugs in terms of toxicity and efficacy.  
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Our study suggest that therapeutic targeting of AMPK → CDK4/6 → FOXM1 → VEGFA 
signaling might be an effective strategy to block angiogenesis in gastric cancer cells, and that small 
molecule inhibitors should be tested in clinical trials against gastric cancer.  
HL156 is a modified compound that is different from metformin with enhanced AMPK activation 
property. Recently repositioning and repurposing of biguanides to treat cancer is an emerging issue for 
cancer treatment 98. HL156 has a documented preclinical safety and efficacy. Therefore, if we establish 
clinical anti-cancer efficacy of HL156, it will help to treat cancer patients more appropriately. 
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Ⅴ. CONCLUSION 
In conclusion, our data elucidate a novel molecular mechanism of new biguanide compounds in 
tumor suppression. We demonstrated that HL156 suppressed angiogenesis through down regulating 
major angiogenic factor VEGFA in human gastric cancer cells. The anti-angiogenic effect was mediated 
through AMPK activation which reduces FOXM1 by downregulation of CDK4/6. Our findings shed 
light on the application of AMPK activators in the treatment of human gastric cancer. 
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Pilot study 
 
 
Pilot Study 1. HL156 compounds inhibit tumor growth in vivo  
HL156 showed comparable tumor growth inhibition effect at lower dose (50mpk) compared to Xeloda 
(100mpk) that is an orally-administered chemotherapeutic agent used in the treatment of numerous 
cancers in xenograft model. 
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Pilot study 2. HL156 compounds inhibit tumor metastasis in vivo 
HL156 showed more than 50% metastasis inhibition effect at lower dose compared to Imatinib 
(100mpk), marketed by Novartis as Gleevec, is a tyrosine-kinase inhibitor used in the treatment of 
multiple cancers. 
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Pilot study 3. Analysis of Reverse phase protein expression array (RPPA) data from 70 gastric cancer 
patients indicated that p-AKT, PAI1, VEGFR2 and p-FOXO3a which related to angiogenesis increased 
in tumors of patients with poor prognosis. 
   
40 
 
Supplementary data 
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Supplementary Figure 1. HL156 compounds inhibit migration of gastric cancer cells 
Wound healing assay for migration was carried out by scratching the cells with yellow tip when gastric 
cancer cells grew into monolayer. Then, cells incubated with the medium with or without HL156  
(30μM) and allowed to migrate into the scratched area for 24 and 48 hours. The arrow showed the gap 
of scratched area and the percentage of migrating cells in wound healing assay quantified. 
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Supplementary Figure 2. HL156 compounds repress expression of FOXM1 in several gastric 
cancer cell lines.  
We tested HL156 not only for MKN28 and AGS cells but also for other gastric cancer lineages including 
NCI-N87, SNU638, and MKN45. We performed immunoblotting with FOXM1 and FOXO3A. The 
expression of FOXO3A was variable depending on cell lineages, but, expression of FOXM1 distinctly 
decreased in all of cell lineages. Thus, we assured that FOXM1 is a target of HL156. 
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Supplementary Figure 3. HL156 influences the expression of various protein levels in MKN28 
cells.  MKN28, a model cell line, is sensitive to HL156, especially to HL156B. Of note, the results 
showed that FOXM1, phosphor FOXM1(Ser35), and CDK4 were coordinately down-regulated.   
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ABSTRACT (IN KOREA) 
 
 
 
 
위암 세포에서 새로운 메트포르민 유도체 HL156 화합물의  
AMPK 경유 FOXM1 억제에 의한 항신생혈관 효과 
 
 
<지도교수 정재호> 
 
연세대학교 대학원 의과학과 
 
최혜지 
 
메트포르민은 널리 사용되고 있는 바이구아니드계 경구형 당뇨 치료제로서 최근에 
항암제로서의 가능성이 제시되고 있다. 하지만 메트포르민의 항암효과의 작용기전은 
분자적 수준에서 잘 밝혀져 있지 않다. HL156 화합물은 메트포르민 분자식을 바탕으로 
개발된 바이구아니드계 유도체로서 다양한 암세포주 대상 선행 실험 결과에서 
메트포르민보다 증가된 AMPK 활성 효과 및 더 뛰어난 항암효과를 보여주었다.  
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선행연구로 수행된 위암환자 종양조직의 단백체 분석 (reverse phase protein array, RPPA) 
결과 신생혈관 관련 단백질 발현과 환자 예후 사이에 유의한 상관 관계가 있음을 확인 
하였다. 또한 마우스 종양 모델에서 HL156 화합물의 전이 억제효과에 기반하여, 저자는 
위암세포모델에서 암전이의 필수단계인 혈관신생 억제에 대한 HL156 화합물의 효과를 
규명하기 위한 연구를 수행하였다. 위암세포에 HL156 화합물을 처리해서 얻은 조건화 
배지를 이용하여 시험관상에서 혈관 내피 세포의 신생혈관이 억제되는 것을 확인하였다. 
또한 조건화 배지에서 주요 신생혈관 유도인자인 VEGFA 의 발현 및 분비량이 유의하게 
감소하는 것을 ELISA 를 통해 확인하였다. 나아가 HL156 처리시 위암세포에서 AMPK 
활성을 통해 VEGFA 유전자 발현을 조절하는 종양형성전사인자인 FOXM1 발현이 
감소하는 것을 확인하였다. 이러한 효과는 FOXM1 을 인산화 시키는 CDK4/6 키나제가 
발현 억제되어 생물학적으로 안정된 형태의 phosho-FOXM1 발현 수준 저하와 상관 
되어있음을 확인 하였다. 마지막으로 electrophoretic mobility shift assay (EMSA) 를 통해 
HL156 처리시 FOXM1 의 VEGFA 프로모터 결합이 억제됨을 확인하였다. 결론적으로 본 
연구 결과는 HL156 화합물에 의한 세포내 AMPK 활성이 CDK4/6 발현을 억제하여 
종양형성전사인자인 FOXM1 의 탈인산화 및 핵내 발현을 감소시키므로서 표적 유전자인 
VEGFA 발현 억제를 통해 혈관신생을 억제하는 새로운 분자 기전을 제시한다.   
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